Bamlanivimab improves hospitalization and mortality rates in patients with COVID-19: A systematic review and meta-analysis

Effect of Bamlanivimab as Monotherapy or in Combination With Etesevimab on Viral Load in Patients With Mild to Moderate COVID-19

(2021) Robert L. Gottlieb et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Bamlanivimab Use in a Military Treatment Facility

(2021) Eric Karr et al.   MILITARY MEDICINE

Neutralising antibody escape of SARS‐CoV‐2 spike protein: Risk assessment for antibody‐based Covid‐19 therapeutics and vaccines

(2021) Daniele Focosi et al.   REVIEWS IN MEDICAL VIROLOGY

Impact of bamlanivimab monoclonal antibody treatment on hospitalization and mortality among non-hospitalized adults with SARS-CoV-2 infection

(2021) J Ryan Bariola et al.   Open Forum Infectious Diseases

Effect of Bamlanivimab vs Placebo on Incidence of COVID-19 Among Residents and Staff of Skilled Nursing and Assisted Living Facilities

(2021) Myron S. Cohen et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Bamlanivimab plus Etesevimab in Mild or Moderate Covid-19

(2021) Michael Dougan et al.   NEW ENGLAND JOURNAL OF MEDICINE

Bamlanivimab use in mild‐to‐moderate COVID‐19 disease: A matched cohort design

(2021) Christopher J. Destache et al.   PHARMACOTHERAPY

The Efficacy of Bamlanivimab in Reducing Emergency Department Visits and Hospitalizations in a Real-world Setting

(2021) Douglas S Corwin et al.   Open Forum Infectious Diseases

SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor

(2020) Markus Hoffmann et al.   CELL

SARS-CoV-2 vaccines in development

(2020) Florian Krammer   NATURE